Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
10.3802/jgo.2013.24.2.167
- Author:
Luis Felipe SALLUM
1
;
Luis Otavio SARIAN
;
Liliana LUCCI DE ANGELO ANDRADE
;
Jose VASSALLO
;
Fernando Augusto SOARES
;
Glauce Aparecida PINTO
;
Patricia Andreia FERREIRA
;
Sophie DERCHAIN
Author Information
1. Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-UNICAMP, Sao Paulo, Brazil. sophie.derchain@pq.cnpq.br
- Publication Type:Original Article
- Keywords:
Borderline ovarian tumor;
Estrogen receptor;
Immunohistochemistry;
Ovarian carcinoma;
Progesterone receptor;
Tissue microarray
- MeSH:
Disease-Free Survival;
Estrogens;
Female;
Humans;
Immunohistochemistry;
Mucins;
Progesterone;
Receptors, Progesterone;
Receptors, Steroid
- From:Journal of Gynecologic Oncology
2013;24(2):167-176
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. METHODS: We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. RESULTS: Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). CONCLUSION: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.
